Show simple item record

dc.contributor.authorKottaridis, Panagiotis D
dc.contributor.authorMilligan, Donald W
dc.contributor.authorChopra, Rajesh
dc.contributor.authorChakraverty, Ronjon
dc.contributor.authorChakrabarti, Suparno
dc.contributor.authorRobinson, Stephen P
dc.contributor.authorPeggs, Karl S
dc.contributor.authorVerfuerth, Stephanie
dc.contributor.authorPettengell, Ruth
dc.contributor.authorMarsh, Judith C W
dc.contributor.authorSchey, Stephen
dc.contributor.authorMahendra, Premini
dc.contributor.authorMorgan, Gareth J
dc.contributor.authorHale, Geoff
dc.contributor.authorWaldmann, Herman
dc.contributor.authorDe Elvira, M Carmen Ruiz
dc.contributor.authorWilliams, Catherine D
dc.contributor.authorDevereux, Stephen
dc.contributor.authorLinch, David C
dc.contributor.authorGoldstone, Anthony H
dc.contributor.authorMackinnon, Stephen
dc.date.accessioned2009-11-19T16:52:44Z
dc.date.available2009-11-19T16:52:44Z
dc.date.issued2000-10-01
dc.identifier.citationIn vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. 2000, 96 (7):2419-25 Blooden
dc.identifier.issn0006-4971
dc.identifier.pmid11001893
dc.identifier.urihttp://hdl.handle.net/10541/86521
dc.description.abstractA novel nonmyeloablative conditioning regimen was investigated in 44 patients with hematologic malignancies. The median patient age was 41 years. Many of the patients had high-risk features, including 19 patients with a previous failed transplant. Recipient conditioning consisted of CAMPATH-1H, 20 mg/day on days -8 to -4; fludarabine, 30 mg/m(2) on days -7 to -3; and melphalan, 140 mg/m(2) on day -2. Thirty-six recipients received unmanipulated granculocyte colony-stimulating factor-mobilized peripheral blood stem cells from HLA-identical siblings, and 8 received unmanipulated marrow from matched unrelated donors. GVHD prophylaxis was with cyclosporine A alone for 38 patients and cyclosporine A plus methotrexate for 6 sibling recipients. Forty-two of the 43 evaluable patients had sustained engraftment. Results of chimerism analysis using microsatellite polymerase chain reaction indicate that 18 of 31 patients studied were full-donor chimeras while the other patients were mixed chimeras in one or more lineages. At a median follow-up of 9 months (range 3 to 29 months), 33 patients remain alive in complete remission or with no evidence of disease progression. Seven patients relapsed or progressed post-transplantation, and 4 of them subsequently died. Four patients died of regimen-related complications. There were no cases of grades III-IV acute GVHD. Only 2 patients developed grade II acute GVHD, and only 1 had chronic GVHD. The estimated probability of nonrelapse mortality was 11%. Although longer follow-up is needed to establish the long-term remission rates, this study demonstrates that this nonmyeloablative preparative regimen is associated with durable engraftment, minimal toxicity, and low incidence of GVHD.
dc.language.isoenen
dc.subjectHaematologic Canceren
dc.subjectHaematopoietic Stem Cell Transplantationen
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntibodies, Neoplasm
dc.subject.meshAntineoplastic Agents
dc.subject.meshCyclosporine
dc.subject.meshDrug Therapy, Combination
dc.subject.meshFemale
dc.subject.meshGraft vs Host Disease
dc.subject.meshGranulocyte Colony-Stimulating Factor
dc.subject.meshHematologic Neoplasms
dc.subject.meshHematopoietic Stem Cell Transplantation
dc.subject.meshHistocompatibility Testing
dc.subject.meshHumans
dc.subject.meshImmunosuppressive Agents
dc.subject.meshMale
dc.subject.meshMelphalan
dc.subject.meshMethotrexate
dc.subject.meshMicrosatellite Repeats
dc.subject.meshMiddle Aged
dc.subject.meshNuclear Family
dc.subject.meshPolymerase Chain Reaction
dc.subject.meshRecurrence
dc.subject.meshTransplantation Chimera
dc.subject.meshTransplantation Conditioning
dc.subject.meshTreatment Outcome
dc.subject.meshVidarabine
dc.titleIn vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.en
dc.typeArticleen
dc.contributor.departmentDepartments of Hematology, University College London Hospital, London, England.en
dc.identifier.journalBlooden
html.description.abstractA novel nonmyeloablative conditioning regimen was investigated in 44 patients with hematologic malignancies. The median patient age was 41 years. Many of the patients had high-risk features, including 19 patients with a previous failed transplant. Recipient conditioning consisted of CAMPATH-1H, 20 mg/day on days -8 to -4; fludarabine, 30 mg/m(2) on days -7 to -3; and melphalan, 140 mg/m(2) on day -2. Thirty-six recipients received unmanipulated granculocyte colony-stimulating factor-mobilized peripheral blood stem cells from HLA-identical siblings, and 8 received unmanipulated marrow from matched unrelated donors. GVHD prophylaxis was with cyclosporine A alone for 38 patients and cyclosporine A plus methotrexate for 6 sibling recipients. Forty-two of the 43 evaluable patients had sustained engraftment. Results of chimerism analysis using microsatellite polymerase chain reaction indicate that 18 of 31 patients studied were full-donor chimeras while the other patients were mixed chimeras in one or more lineages. At a median follow-up of 9 months (range 3 to 29 months), 33 patients remain alive in complete remission or with no evidence of disease progression. Seven patients relapsed or progressed post-transplantation, and 4 of them subsequently died. Four patients died of regimen-related complications. There were no cases of grades III-IV acute GVHD. Only 2 patients developed grade II acute GVHD, and only 1 had chronic GVHD. The estimated probability of nonrelapse mortality was 11%. Although longer follow-up is needed to establish the long-term remission rates, this study demonstrates that this nonmyeloablative preparative regimen is associated with durable engraftment, minimal toxicity, and low incidence of GVHD.


This item appears in the following Collection(s)

Show simple item record